- Home
- OLO vs AVBP Comparison
OLO vs AVBP Comparison
Compare OLO & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- AVBP
- Stock Information
- Founded
- OLO 2005
- AVBP 2021
- Country
- OLO United States
- AVBP United States
- Employees
- OLO N/A
- AVBP N/A
- Industry
- OLO Major Banks
- AVBP
- Sector
- OLO Finance
- AVBP
- Exchange
- OLO Nasdaq
- AVBP NYSE
- Market Cap
- OLO 1.0B
- AVBP 862.8M
- IPO Year
- OLO 2021
- AVBP 2024
- Fundamental
- Price
- OLO $10.48
- AVBP $19.51
- Analyst Decision
- OLO Buy
- AVBP Strong Buy
- Analyst Count
- OLO 3
- AVBP 8
- Target Price
- OLO $10.17
- AVBP $38.38
- AVG Volume (30 Days)
- OLO 6.5M
- AVBP 246.3K
- Earning Date
- OLO 08-04-2025
- AVBP 08-13-2025
- Dividend Yield
- OLO N/A
- AVBP N/A
- EPS Growth
- OLO N/A
- AVBP N/A
- EPS
- OLO 0.01
- AVBP N/A
- Revenue
- OLO $299,107,000.00
- AVBP N/A
- Revenue This Year
- OLO $20.21
- AVBP N/A
- Revenue Next Year
- OLO $17.90
- AVBP N/A
- P/E Ratio
- OLO $979.26
- AVBP N/A
- Revenue Growth
- OLO 23.31
- AVBP N/A
- 52 Week Low
- OLO $4.56
- AVBP $15.47
- 52 Week High
- OLO $10.55
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- OLO 81.66
- AVBP 34.24
- Support Level
- OLO $10.12
- AVBP $21.10
- Resistance Level
- OLO $10.55
- AVBP $22.29
- Average True Range (ATR)
- OLO 0.04
- AVBP 1.01
- MACD
- OLO -0.02
- AVBP -0.23
- Stochastic Oscillator
- OLO 84.71
- AVBP 8.41
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.